CARD9 and in situ carcinoma: Gene expression analysis revealed a significant increase in MINCLE and one of the downstream mediators, CARD9, in CIS patients and relapsing-remitting MS (RRMS) patients during relapse compared with NINDCs (Figure 6B and Supplemental Figure 7C).